Subscribe to our newsletter

Send us a link

Do Last Week's European Copyright Votes Show Publishers Have Captured European Politics?

Do Last Week's European Copyright Votes Show Publishers Have Captured European Politics?

A small change would open up a whole new class of works for which publishers could demand payment for the use of small snippets, apparently including works that the author had released under an open access license.

Science to Participate in bioRxiv’s Manuscript Transfer Service

Science to Participate in bioRxiv’s Manuscript Transfer Service

Authors will have the opportunity to submit their manuscripts directly for consideration to Science.

Authorea and BioRxiv Partner to Bring Preprints into 21st Century

Authorea and BioRxiv Partner to Bring Preprints into 21st Century

Authorea, the collaborative document editor for researchers, announced a partnership and direct submission agreement with bioRxiv, the leading preprint server for biological research.

Study Finds Large Share of Cases Involving Faculty Harassment of Graduate Students Are Serious

Study Finds Large Share of Cases Involving Faculty Harassment of Graduate Students Are Serious

New study of harassment of graduate students by faculty members suggests that the problem is worse -- both in level of offense and prevalence of repeat offenders -- than many believe.

Research Funding: The Case for a Modified Lottery

Research Funding: The Case for a Modified Lottery

On awarding research funds on the basis of a modified lottery in which peer review is used to identify the most meritorious proposals, from which funded applications are selected by lottery.

The Reproducibility of Research and the Misinterpretation of P-Values

The Reproducibility of Research and the Misinterpretation of P-Values

Science is endangered by statistical misunderstanding, and by university presidents and research funders who impose perverse incentives on scientists.

Big Pharma Buys Into Crowdsourcing for Drug Discovery

Big Pharma Buys Into Crowdsourcing for Drug Discovery

The Structural Genomics Consortium encourages pharma companies and academics to put all their cards on the table in the interest of speeding up drug research.